Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991459 | 0.98 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TP53KDM4EGMNN | |
| SCHEMBL4992239 | 0.97 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2TP53KDM4EGMNN | |
| SCHEMBL4990963 | 0.93 | SLC1A3 (0.38) | ALDH1A1SMN1; SMN2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4986802 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2TP53KDM4EGMNN | |
| SCHEMBL27488749 | 0.80 | GABRR1 (0.45) | ALDH1A1SMN1; SMN2LMNABLMEPHX1 | |
| SCHEMBL4993073 | 0.79 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TP53KDM4EGMNN | |
| SCHEMBL27488386 | 0.78 | GABRR1 (0.43) | ALDH1A1SMN1; SMN2BLMEPHX1GABRR1 | |
| SCHEMBL3995531 | 0.77 | CPB2 (0.41) | SLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL3991829 | 0.77 | CPB2 (0.41) | SLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL4990481 | 0.77 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TP53SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948149-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | Aldeyra Therapeutics, Inc. (US) | 2015-12-02 | — | — | EP | claimed |
| WO-2014116836-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | claimed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-2948149-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | Aldeyra Therapeutics, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014116836-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | ALDH1A1 1484/4885SMN1; SMN2 1368/4885TP53 4213/4885 |
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 1212/4885TP53 4481/4885 |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 1212/4885TP53 4481/4885 |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 1212/4885TP53 4481/4885 |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 1212/4885TP53 4481/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 1212/4885TP53 4481/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 1212/4885TP53 4481/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | ALDH1A1 1627/4885SMN1; SMN2 1347/4885TP53 4527/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ALDH1A1 1424/4885SMN1; SMN2 1393/4885TP53 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.